Where Teva failed, Eli Lilly gained — migraine drug Emgality wins US approval for episodic cluster headaches
It may be trailing behind its rivals in migraine sales, but Lilly’s Emgality has secured the FDA nod for episodic cluster headaches.
Emgality was the last injectable to win approval for migraine prevention last September, months after Aimovig from Amgen $AMGN and Novartis $NVS, and Teva’s {$TEVA] Ajovy. All three form part of a family of drugs developed to block calcitonin gene-related peptide (CGRP), a protein associated with the onset of migraine pain. Each has demonstrated a significant reduction in migraine frequency in about half of patients when tested in clinical studies and is priced at $6,900 a year, or $575 per month. Tiny Alder’s $ALDR CGRP is under FDA review.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.